1 Dipartimento di Neuroscienze e Tecnologie Biomediche and 4 Dipartimento di Scienze Chirurgiche, Università di Milano Bicocca, Monza; 2 Clinica Neurologica and 5 Clinica Ginecologica, A.O. S. Gerardo, Monza; 3 Dipartimento di Ginecologia Oncologica, Istituto Europeo di Oncologia, Milano; 6 Sigma-Tau ifr, Pomezia, Italy
* Correspondence to: Professor Guido Cavaletti, Clinica Neurologica, Ospedale S. Gerardo, V. Donizetti 106, 20052 Monza, Italy. Tel: +39-039-233-2379; Fax: +39-02-700-438-655; Email: guido.cavaletti{at}unimib.it
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Patients and methods: Sixty-two women affected by locally advanced squamous cervical carcinoma treated with TP (paclitaxel 175 mg/m2 over a 3 h infusion plus cisplatin 75 mg/m2) or TIP (TP plus ifosphamide 5 mg/m2) were examined and scored according to the Total Neuropathy Score (TNS), before and during chemotherapy.
Results: A correlation with the final severity of CIPN was observed with vibration perception and deep tendon reflex evaluation, while pin sensibility, strength, and autonomic symptoms and signs were not informative. A highly significant correlation existed between the decrease in circulating levels of NGF and the severity of CIPN (r=0.579; P <0.001; 95% confidence limits 0.702 to 0.423). However, circulating levels of NGF were not effective as predictors of the final neurological outcome of each patient.
Conclusion: Our study indicates that a precise clinical evaluation of the peripheral nervous system of patients treated with platinum and taxane combination polychemotherapy not only gives reliable information regarding the course of CIPN, but also can be used to predict the final neurological outcome of the treatment.
Key words: chemotherapy, cisplatin, neuropathy, paclitaxel
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Moreover, evidence that nerve growth factor (NGF) may play a role in the course of CIPN has recently been reported [49
], but this result has not yet been confirmed in prospective studies on patients followed using clinical and neurophysiological methods.
The main aim of this study was to investigate the possible use of the Total Neuropathy Score (TNS) or of individual TNS items to predict the outcome of CIPN in patients undergoing cisplatin and paclitaxel combination chemotherapy, and to assess circulating NGF levels in relationship to the neurological status in order to determine whether a correlation exists between biological and clinical indicators of the final neurological outcome.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
All the patients participating in this study, some of whom belonged to the cohort reported in the TNS validation study [3], were examined at the Department of Neurology of the S. Gerardo Hospital. Neurological examinations were performed before chemotherapy, after three and five cycles, and 3 months after the end of chemotherapy. The severity of CIPN was assessed by a single examiner (G.C.) and the TNS score (Table 1) was calculated.
|
At the time of each neurological examination, a venous blood sample was obtained and plasma was stored at 80°C until determination of the NGF level by enzyme-linked immunosorbent assay using a commercial kit [EmaxTM ImmunoAssay System (Promega, Madison, WI)] [9].
The correlations existing between total TNS and circulating levels of NGF were assessed using the Spearman test for non-parametric data (significance level P <0.05), and the 95% confidence limits were also calculated using PRISM (GraphPad Software, Inc., CA).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
During the examinations performed before the maximum severity of CIPN had been reached, the total TNS score increased by 38 points in the group that eventually had the worst final neurological signs and symptoms, and by 05 points in the group with the better overall outcome. However, the most interesting correlation with the final severity of CIPN (Table 2) was observed in the subscore obtained for the items regarding vibration perception and DTR, while pin sensibility, strength, and autonomic symptoms and signs were not informative. In fact, in the examination performed before the onset of worst neuropathy signs, 14 of the 15 patients with a final TNS of 10 had a change of
2 points in the score obtained by adding together the vibration score obtained with the tuning fork and the DTR examination. Interestingly, in 12 of these 14 patients, the change in the score was due to both vibration perception and DTR impairment. This observation is relevant since a change in the combined score (i.e. vibration + DTR impairment
2 points) was also observed in seven of the 14 patients in the group with the better neurological outcome, but none experienced any change in vibration perception at the examination performed before the maximum TNS score was reached. Another possible early indicator for worse neurological outcome was the complete disappearance of DTR in the lower limbs, which was observed in seven of the 15 patients, while only one patient in the better outcome group had this clinical sign. The results of the VDT score were in agreement with the tuning fork results, while the neurophysiological assessment of sural nerve potential amplitude changes was less effective than clinical or VDT examinations in predicting the final outcome of the CIPN (Table 2).
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
General agreement regarding the best way to investigate and grade the peripheral neurotoxicity of platinum drugs has not yet been reached [13
, 10
, 13
, 14
].
In our study, careful examination of changes in vibration sensibility and DTR was found to be an early predictor of the outcome of CIPN. Moreover, vibration impairment, assessed using a tuning fork in the semiquantitative manner described in our study, was particularly effective. Neurophysiological assessment allows reproducible results to be obtained, but these methods are most useful for grading an established neuropathy rather than for predicting a better or worse outcome, as the present study has also confirmed. Neuroradiological methods [15] of studying spinal cord dorsal columns still need to be validated in large series to assess sensitivity and reliability. Sural nerve biopsy is no longer an acceptable method for investigating well established chemotherapy schedules. Skin biopsy, however, might be a useful tool in the future. In fact, in diabetic patients, skin biopsy changes in the intraepidermal innervation occur very early in the course of the disease, and the procedure is simple and well tolerated by patients [16
, 17
]. However, until now no validation of skin biopsy results has been performed in the course of CIPN.
In searching for a biological marker for CIPN, and possibly for a predictor of the neurological outcome, we investigated a large number of serial NGF samples obtained during the course of the study. NGF, a neurotrophic factor of the neurotrophin family, has been investigated as a putative neuroprotectant in several in vitro and in vivo models of cisplatin and paclitaxel peripheral neurotoxicity [58
, 18
, 19
]. Moreover, a previous small clinical study performed in an unselected cohort of patients undergoing various chemotherapy schedules, suggested that circulating NGF levels might be correlated with clinical status [9
, 20
]. These results have already been reproduced in cisplatin and oxaliplatin rat models [21
], while no data are available on taxanes. Our study made it possible to confirm that cisplatinpaclitaxel chemotherapy determines a clinically related decrease in NGF circulating levels, but it failed to demonstrate that determining NGF is a biological predictor of final neurological outcome.
In conclusion, our study indicates that a precise clinical evaluation of the peripheral nervous system of patients treated with platinumtaxane combination polychemotherapy yields reliable information not only about the course of CIPN, but that it can be also be used to predict the final neurological outcome of the treatment.
Received for publication March 7, 2004. Revision received April 26, 2004. Accepted for publication May 4, 2004.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Postma TJ, Heimans JJ, Muller MJ et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998; 9: 739744.[Abstract]
3. Cavaletti G, Bogliun G, Marzorati L et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003; 61: 12971300.
4. Aloe L, Manni L, Properzi F et al. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 2000; 86: 8493.[CrossRef][ISI][Medline]
5. Apfel SC, Arezzo JC, Lipson LA, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992; 31: 7680.[ISI][Medline]
6. Schmidt Y, Unger I, Bartke R, Reiter R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (cd/db) mice. Exp Neurol 1995; 132: 1623.[CrossRef][ISI][Medline]
7. Tredici G, Braga M, Nicolini G et al. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 1999; 159: 551558.[CrossRef][ISI][Medline]
8. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 8790.[ISI][Medline]
9. Cavaletti G, Pezzoni G, Pisano C et al. Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett 2002; 322: 103106.[CrossRef][ISI][Medline]
10. Cavaletti G, Marzorati L, Bogliun G et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992; 69: 203207.[ISI][Medline]
11. Zaslansky R, Yarnitsky D. Clinical applications of quantitative sensory testing (QST). J Neurol Sci 1998; 153: 215238.[CrossRef][ISI][Medline]
12. Cavaletti G, Bogliun G, Marzorati L et al. The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. J Neurol 1991; 238: 371374.[ISI][Medline]
13. Cavaletti G, Bogliun G, Marzorati L et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995; 75: 11411150.[ISI][Medline]
14. Cavaletti G, Bogliun G, Crespi V et al. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 1997; 15: 199206.[Abstract]
15. Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 2000; 47: 104109.[CrossRef][ISI][Medline]
16. Lauria G, McArthur JC, Hauer P et al. Neuropathologic alterations in diabetic truncal neuropathy: evaluation by skin biopsy. J Neurol Neurosurg Psychiatry 1998; 65: 762766.
17. Lauria G, Holland N, Hauer P et al. Epidermal innervation: changes with aging, topographic location, and in sensory neuropathy. J Neurol Sci 1999; 164: 172178.[CrossRef][ISI][Medline]
18. Konings PNM, Makkink WK, van Delft AML, Ruigt GSF. Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res 1994; 640: 195204.[CrossRef][ISI][Medline]
19. Malgrange B, Delrée P, Rigo JM et al. Image analysis of neurite regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and its prevention by nerve growth factor or fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Meth 1994; 53: 111122.[CrossRef][ISI][Medline]
20. Cavaletti G, Petruccioli MG, Marmiroli P et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res 2002; 22: 41994204.[ISI][Medline]
21. De Santis S, Pace A, Bove L et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000; 6: 9095.